Skip to main content
Premium Trial:

Request an Annual Quote

Australia's VCGS Inks Deal with Illumina to Develop NIPT

NEW YORK (GenomeWeb) – Victorian Clinical Genetics Services, a genetic testing subsidiary of the Murdoch Children's Research Institute in Melbourne, Australia, has struck a deal with Illumina for non-invasive prenatal testing.

Under the agreement, VCGS will develop its own non-invasive prenatal test using Illumina's sequencing technology, which it will begin offering in early 2015. Prior to launching its own test, VCGS will send samples to Illumina for testing. 

"This agreement positions VCGS at the frontier of prenatal testing in Australia, and offers patients exciting and powerful new options for genetic testing," Damien Bruno, deputy laboratory director at VCGS, said in a statement. 

VCGS currently provides maternal serum screening for more than 58,000 women annually. It also offers genetic services, including genetic counseling and education.

Earlier this year, VCGS published on a method in PLOS One to reduce coverage bias from shotgun sequencing in order to improve accuracy of detecting aneuploidy.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.